In this context, Martinez-Rodriguez et al. explored the expression of NKG2C on NK cells from MS patients and controls, in relation to their CMV+ serostatus and to the NKG2C genotype, finding that the expansion of NKG2C+ NK cells in CMV+ patients was associated to lower risk of disease progression, suggesting that CMV may exert a beneficial influence on MS, either through expansion of NKG2C+ NK cells or through other mechanisms (58). Here, KLRC2 is linked to myeloid sarcoma.